ES2386578T3
(es)
|
2006-05-05 |
2012-08-23 |
Isis Pharmaceuticals, Inc. |
Compuestos y procedimientos para modular la expresión de PCSK9
|
JP5665317B2
(ja)
*
|
2006-10-18 |
2015-02-04 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
アンチセンス化合物
|
DK2149605T3
(da)
*
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
WO2009046426A2
(en)
*
|
2007-10-04 |
2009-04-09 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for improving cellular uptake of oligomeric compounds
|
WO2009124295A2
(en)
*
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
MX2011004097A
(es)
|
2008-10-15 |
2011-07-28 |
Isis Pharmaceuticals Inc |
Modulacion de la expresion del factor 11.
|
RU2015151857A
(ru)
|
2008-12-02 |
2019-01-15 |
Уэйв Лайф Сайенсес Джапан, Инк. |
Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
|
AU2010270714B2
(en)
|
2009-07-06 |
2015-08-13 |
Wave Life Sciences Ltd. |
Novel nucleic acid prodrugs and methods use thereof
|
US9006198B2
(en)
|
2010-02-08 |
2015-04-14 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
EP3561060A1
(de)
|
2010-02-08 |
2019-10-30 |
Ionis Pharmaceuticals, Inc. |
Selektive reduktion von allelvarianten
|
CN106434648A
(zh)
*
|
2010-07-19 |
2017-02-22 |
F·C·贝内特 |
肌强直性营养障碍蛋白激酶(dmpk)表达的调节
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
AU2011325956B2
(en)
|
2010-11-12 |
2016-07-14 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
CA3077910A1
(en)
|
2010-11-17 |
2012-05-24 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
EP2673361B1
(de)
|
2011-02-08 |
2016-04-13 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und ihre verwendung
|
WO2012161806A1
(en)
*
|
2011-02-25 |
2012-11-29 |
Isis Pharmaceuticals, Inc. |
Modulation of stat3 expression
|
LT3505528T
(lt)
|
2011-04-21 |
2021-04-26 |
Glaxo Group Limited |
Hepatito b viruso (hbv) raiškos moduliacija
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
CN107365339A
(zh)
|
2011-07-19 |
2017-11-21 |
波涛生命科学有限公司 |
合成官能化核酸的方法
|
US9752142B2
(en)
|
2011-08-11 |
2017-09-05 |
Ionis Pharmaceuticals, Inc. |
Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof
|
EP2756080B1
(de)
|
2011-09-14 |
2019-02-20 |
Translate Bio MA, Inc. |
Multimere oligonukleotidverbindungen
|
US9243291B1
(en)
*
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
WO2013138353A2
(en)
*
|
2012-03-12 |
2013-09-19 |
Shire Human Genetic Therapies, Inc. |
Compositions and methods for modulation of atxn3 expression
|
EP3336189A1
(de)
|
2012-04-20 |
2018-06-20 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
AU2013262649A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
WO2013173645A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating utrn expression
|
JP2015519057A
(ja)
*
|
2012-05-16 |
2015-07-09 |
ラナ セラピューティクス インコーポレイテッド |
Pten発現を調節するための組成物及び方法
|
EA201492120A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии atp2a2
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
AU2013262700A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating hemoglobin gene family expression
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
WO2013173789A2
(en)
|
2012-05-17 |
2013-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
DK2855500T3
(da)
|
2012-05-24 |
2020-09-14 |
Ionis Pharmaceuticals Inc |
Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression
|
US9487780B2
(en)
|
2012-06-01 |
2016-11-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
US9828602B2
(en)
|
2012-06-01 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
AU2013287630B2
(en)
|
2012-07-13 |
2017-05-25 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant
|
CA2879023C
(en)
|
2012-07-13 |
2017-03-28 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
CN104661664B
(zh)
|
2012-07-13 |
2020-07-03 |
波涛生命科学有限公司 |
手性控制
|
JP2015529469A
(ja)
|
2012-09-14 |
2015-10-08 |
ラナ セラピューティクス インコーポレイテッド |
多量体オリゴヌクレオチド化合物
|
EP2906699A4
(de)
|
2012-10-11 |
2016-06-08 |
Ionis Pharmaceuticals Inc |
Oligomere verbindungen mit bicyclischen nukleosiden und verwendungen davon
|
US20160138014A1
(en)
*
|
2012-10-12 |
2016-05-19 |
Isis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
JP6574383B2
(ja)
*
|
2012-12-05 |
2019-09-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
PCSK9iRNA組成物及びその使用方法
|
JP6440170B2
(ja)
|
2013-03-01 |
2018-12-19 |
国立大学法人 東京医科歯科大学 |
キメラ一本鎖アンチセンスポリヌクレオチドおよび二本鎖アンチセンス剤
|
PL2970974T3
(pl)
*
|
2013-03-14 |
2018-01-31 |
Alnylam Pharmaceuticals Inc |
Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania
|
RU2650510C2
(ru)
|
2013-05-01 |
2018-04-16 |
Ионис Фармасьютикалз, Инк. |
Композиции и способы модулирования экспрессии аполипопротеина c-iii
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
WO2015084884A2
(en)
|
2013-12-02 |
2015-06-11 |
Isis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
JPWO2015108046A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
EP3095461A4
(de)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
KR20230152178A
(ko)
|
2014-01-16 |
2023-11-02 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
RS62526B1
(sr)
|
2014-03-19 |
2021-11-30 |
Ionis Pharmaceuticals Inc |
Kompozicije za modulaciju ekspresije ataksina 2
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
EP4137573A3
(de)
|
2014-04-01 |
2023-05-03 |
Biogen MA Inc. |
Zusammensetzungen zur modulierung der sod-1-expression
|
CR20200228A
(es)
|
2014-05-01 |
2020-07-09 |
Ionis Pharmaceuticals Inc |
COMPOSICIONES Y MÈTODOS PARA MODULAR LA EXPRESIÒN DEL FACTOR B DEL COMPLEMENTO (Divisional 2016-0554)
|
WO2015187989A1
(en)
|
2014-06-04 |
2015-12-10 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting apolipoprotein e receptor 2
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
WO2015200697A1
(en)
|
2014-06-25 |
2015-12-30 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
WO2016040748A1
(en)
|
2014-09-12 |
2016-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for detection of smn protein in a subject and treatment of a subject
|
WO2016041058A1
(en)
|
2014-09-18 |
2016-03-24 |
The University Of British Columbia |
Allele-specific therapy for huntington disease haplotypes
|
JP6867945B2
(ja)
|
2014-10-03 |
2021-05-12 |
コールド スプリング ハーバー ラボラトリー |
核内遺伝子出力の標的とされた増強
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
EP3221329A1
(de)
*
|
2014-11-19 |
2017-09-27 |
Roche Innovation Center Copenhagen A/S |
Lna-gapmer-oligonukleotide mit chiralen phosphorthioatverbindungen
|
DK3234131T3
(da)
|
2014-12-16 |
2020-06-29 |
Roche Innovation Ct Copenhagen As |
Fremgangsmåde til screening af kiral toksicitet
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
CN107636159B
(zh)
|
2015-02-04 |
2022-06-14 |
百时美施贵宝公司 |
选择治疗性分子的方法
|
EP3253875B1
(de)
|
2015-02-04 |
2020-01-08 |
H. Hoffnabb-La Roche Ag |
Tau-antisense-oligomere und verwendungen davon
|
EP3256592A4
(de)
*
|
2015-02-13 |
2018-09-12 |
Translate Bio Ma, Inc. |
Zusammensetzungen und verfahren zur rna-modulation
|
EP3256591A4
(de)
|
2015-02-13 |
2018-08-08 |
Translate Bio Ma, Inc. |
Hybride oligonukleotide und verwendungen davon
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
US10900036B2
(en)
|
2015-03-17 |
2021-01-26 |
The General Hospital Corporation |
RNA interactome of polycomb repressive complex 1 (PRC1)
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
MA43072A
(fr)
*
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
US10533175B2
(en)
|
2015-09-25 |
2020-01-14 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Ataxin 3 expression
|
WO2017060731A1
(en)
|
2015-10-09 |
2017-04-13 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
EP3389670A4
(de)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur behandlung von brustkrebs
|
SG11201804443UA
(en)
|
2015-12-14 |
2018-06-28 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
US10907160B2
(en)
|
2016-01-05 |
2021-02-02 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
WO2017142054A1
(ja)
|
2016-02-17 |
2017-08-24 |
国立大学法人東京工業大学 |
人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
MA45270A
(fr)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
CA3023514A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
WO2018055577A1
(en)
*
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
EP3516061A1
(de)
|
2016-09-23 |
2019-07-31 |
Synthena AG |
Gemischte tricyclo-rna-,2'-modifizierte rna-oligonukleotid-zusammensetzungen und verwendungen davon
|
US11260134B2
(en)
|
2016-09-29 |
2022-03-01 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded nucleic acid complex having overhang
|
US11400161B2
(en)
|
2016-10-06 |
2022-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
EP3548005A4
(de)
|
2016-11-29 |
2020-06-17 |
Puretech Health LLC |
Exosome zur ausgabe von therapeutischen wirkstoffen
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
BR112019014547A2
(pt)
|
2017-02-06 |
2020-02-18 |
Nissan Chemical Corporation |
Oligonucleotídeo de fita simples
|
JP7095893B2
(ja)
|
2017-02-21 |
2022-07-05 |
国立大学法人大阪大学 |
アンチセンスオリゴ核酸
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
US20200115710A1
(en)
|
2017-06-30 |
2020-04-16 |
National University Corporation Tokyo Medical And Dental University |
HETERO DOUBLE-STRANDED antimiR
|
KR20200035301A
(ko)
*
|
2017-08-08 |
2020-04-02 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 조성물 및 이의 방법
|
AU2018318231A1
(en)
|
2017-08-18 |
2020-02-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
LT3673080T
(lt)
|
2017-08-25 |
2023-12-27 |
Stoke Therapeutics, Inc. |
Priešprasminiai oligomerai, skirti būklėms ir ligoms gydyti
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
CN111226114A
(zh)
|
2017-10-13 |
2020-06-02 |
罗氏创新中心哥本哈根有限公司 |
用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
|
TWI816066B
(zh)
|
2017-10-16 |
2023-09-21 |
瑞士商赫孚孟拉羅股份公司 |
用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
JP2021505175A
(ja)
|
2017-12-11 |
2021-02-18 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Fndc3bの発現を調節するためのオリゴヌクレオチド
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
EP3729095A1
(de)
|
2017-12-21 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Begleitdiagnostik für htra1-rna-antagonisten
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
CN111448316A
(zh)
|
2017-12-22 |
2020-07-24 |
罗氏创新中心哥本哈根有限公司 |
新的硫代亚磷酰胺
|
CA3085406A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
WO2019122282A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
JP2021511022A
(ja)
|
2018-01-10 |
2021-05-06 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Pias4発現を調節するためのオリゴヌクレオチド
|
EP3737760A1
(de)
|
2018-01-12 |
2020-11-18 |
Roche Innovation Center Copenhagen A/S |
Oligonukleotide zur modulierung der gsk3b-expression
|
CN111902537A
(zh)
|
2018-01-15 |
2020-11-06 |
Ionis制药公司 |
Dnm2表达的调节剂
|
CN111615558A
(zh)
|
2018-01-17 |
2020-09-01 |
罗氏创新中心哥本哈根有限公司 |
用于调节erc1表达的寡核苷酸
|
JP2021511029A
(ja)
|
2018-01-18 |
2021-05-06 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Srebp1を標的とするアンチセンスオリゴヌクレオチド
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
KR20200108315A
(ko)
|
2018-02-09 |
2020-09-17 |
제넨테크, 인크. |
Tmem106b의 발현을 조절하기 위한 올리고뉴클레오티드
|
JP7317029B2
(ja)
|
2018-02-12 |
2023-07-28 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
修飾化合物及びその使用
|
US11674141B2
(en)
|
2018-02-28 |
2023-06-13 |
National University Corporation Tokyo Medical And Dental University |
Ischemic-lesion-site-specific gene therapy
|
WO2019169243A1
(en)
|
2018-03-02 |
2019-09-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-beta precursor protein
|
CN111886011B
(zh)
|
2018-03-02 |
2024-03-08 |
Ionis制药公司 |
Irf4表达的调节剂
|
WO2019177061A1
(ja)
|
2018-03-14 |
2019-09-19 |
国立大学法人東京医科歯科大学 |
核酸複合体
|
EP3769769A4
(de)
|
2018-03-19 |
2022-05-04 |
National University Corporation Tokyo Medical and Dental University |
Nukleinsäure mit reduzierter toxizität
|
EP3770256A4
(de)
|
2018-03-20 |
2021-12-22 |
Tokyo Institute of Technology |
Antisense-oligonukleotid mit reduzierter toxizität
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
WO2019182109A1
(ja)
|
2018-03-22 |
2019-09-26 |
国立大学法人東京医科歯科大学 |
ヘテロ核酸のbbb通過脂質リガンド
|
SG11202008660TA
(en)
|
2018-04-11 |
2020-10-29 |
Ionis Pharmaceuticals Inc |
Modulators of ezh2 expression
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
BR112020021253A2
(pt)
|
2018-05-09 |
2021-02-02 |
Ionis Pharmaceuticals, Inc. |
compostos e métodos para redução da expressão de atxn3
|
MX2020011913A
(es)
|
2018-05-09 |
2021-01-29 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para la reduccion de la expresion de fxi.
|
WO2019233921A1
(en)
|
2018-06-05 |
2019-12-12 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
US11833168B2
(en)
|
2018-06-14 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
PE20210346A1
(es)
*
|
2018-07-03 |
2021-02-25 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de tau
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
JP7411632B2
(ja)
|
2018-07-25 |
2024-01-11 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Atxn2発現を低減するための化合物及び方法
|
JP7182308B2
(ja)
|
2018-07-27 |
2022-12-02 |
国立大学法人大阪大学 |
老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
|
WO2020025527A1
(en)
|
2018-07-31 |
2020-02-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
WO2020025563A1
(en)
|
2018-07-31 |
2020-02-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
JP2021533200A
(ja)
|
2018-08-02 |
2021-12-02 |
ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. |
顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
EP3620519A1
(de)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Verwendung von isolierten extrazellulären vesikeln aus milch zur oralen verabreichung von oligonukleotiden
|
EP3873920A1
(de)
|
2018-11-01 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Gegen tia1 gerichtete antisense-oligonukleotide
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
EP3880821A4
(de)
|
2018-11-15 |
2023-01-25 |
Ionis Pharmaceuticals, Inc. |
Modulatoren der irf5-expression
|
EP3898975A2
(de)
|
2018-12-21 |
2021-10-27 |
Boehringer Ingelheim International GmbH |
Gegen card9 gerichtete antisense-oligonukleotide
|
CN113365607A
(zh)
|
2019-01-25 |
2021-09-07 |
豪夫迈·罗氏有限公司 |
用于口服药物递送的脂质囊泡
|
CN113395971A
(zh)
|
2019-01-31 |
2021-09-14 |
Ionis制药公司 |
Yap1表达的调节剂
|
EP3927716A1
(de)
|
2019-02-20 |
2021-12-29 |
Roche Innovation Center Copenhagen A/S |
Neuartige phosphoramidite
|
TW202102516A
(zh)
|
2019-02-20 |
2021-01-16 |
丹麥商羅氏創新中心哥本哈根有限公司 |
膦醯基乙酸酯間隙子寡核苷酸
|
CN113474633A
(zh)
|
2019-02-26 |
2021-10-01 |
罗氏创新中心哥本哈根有限公司 |
寡核苷酸配制方法
|
WO2020176771A1
(en)
|
2019-02-27 |
2020-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of malat1 expression
|
WO2020184700A1
(ja)
|
2019-03-14 |
2020-09-17 |
レナセラピューティクス株式会社 |
Ihh発現を調節するための核酸複合体
|
JP2022527105A
(ja)
|
2019-03-29 |
2022-05-30 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Ube3a-atsを調節するための化合物及び方法
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
WO2020209285A1
(ja)
|
2019-04-08 |
2020-10-15 |
国立大学法人東京医科歯科大学 |
筋疾患治療用医薬組成物
|
WO2020245233A1
(en)
|
2019-06-06 |
2020-12-10 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
US11786546B2
(en)
|
2019-07-26 |
2023-10-17 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating GFAP
|
JPWO2021054370A1
(de)
|
2019-09-18 |
2021-03-25 |
|
|
EP4043565A4
(de)
|
2019-10-11 |
2024-01-24 |
National University Corporation Tokyo Medical and Dental University |
Modifizierte heteronukleinsäure
|
US20240116977A1
(en)
|
2019-10-11 |
2024-04-11 |
Sumitomo Chemical Company, Limited |
Method for producing nucleic acid oligomers
|
EP4067489A4
(de)
*
|
2019-11-27 |
2024-06-12 |
Tokyo Institute of Technology |
Verfahren zur verminderung der toxizität von antisense-nukleinsäuren
|
MX2022007908A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
|
EP4081217A1
(de)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmazeutische kombination von antivirusmitteln, die hbv und/oder einen immunmodulator zur behandlung von hbv steuern
|
EP4097234A1
(de)
|
2020-01-28 |
2022-12-07 |
Université de Strasbourg |
Antisense-oligonukleotid mit abzielung auf linc00518 zur behandlung von melanomen
|
DK4097117T3
(da)
|
2020-01-29 |
2024-07-22 |
Sumitomo Chemical Company Ltd |
Fremgangsmåde til fremstilling af nukleinsyreoligomer
|
JPWO2021153047A1
(de)
|
2020-01-29 |
2021-08-05 |
|
|
US20230127437A1
(en)
|
2020-01-31 |
2023-04-27 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Antisense oligonucleotide of atn1
|
BR112022016238A2
(pt)
|
2020-02-28 |
2022-10-11 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para modular smn2
|
US20230159925A1
(en)
|
2020-03-04 |
2023-05-25 |
Nissan Chemical Corporation |
Antisense oligonucleotide of calm2
|
WO2021178374A2
(en)
*
|
2020-03-05 |
2021-09-10 |
Synerk Inc. |
Compounds and methods for reducing apoe expression
|
US20230174981A1
(en)
|
2020-03-16 |
2023-06-08 |
National University Corporation Tokyo Medical And Dental University |
Heteronucleic acid containing morpholino nucleic acid
|
EP4130018A4
(de)
|
2020-03-27 |
2024-04-17 |
Sumitomo Chemical Company, Limited |
Verfahren zur herstellung eines nukleinsäureoligomers
|
MX2022013707A
(es)
|
2020-05-01 |
2022-12-07 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular atxn1.
|
MX2022014151A
(es)
|
2020-05-11 |
2022-11-30 |
Stoke Therapeutics Inc |
Oligomeros antisentido de opa1 para tratamiento de afecciones y enfermedades.
|
EP4172338A2
(de)
|
2020-06-29 |
2023-05-03 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulierung von plp1
|
EP4180442A1
(de)
|
2020-07-09 |
2023-05-17 |
Sumitomo Chemical Company, Limited |
Verfahren zur herstellung eines nukleinsäureoligomers
|
KR20230074205A
(ko)
|
2020-09-24 |
2023-05-26 |
스미또모 가가꾸 가부시끼가이샤 |
핵산 올리고머의 제조 방법
|
KR20230108728A
(ko)
|
2020-11-18 |
2023-07-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
|
WO2022117747A2
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
US20220177883A1
(en)
|
2020-12-03 |
2022-06-09 |
Hoffmann-La Roche Inc. |
Antisense Oligonucleotides Targeting ATXN3
|
TW202242111A
(zh)
|
2020-12-18 |
2022-11-01 |
美商Ionis製藥公司 |
用於調節因子xii之化合物及方法
|
WO2022162015A1
(en)
|
2021-01-26 |
2022-08-04 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
WO2022241408A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating tissue distribution of intracellular therapeutics
|
CA3219942A1
(en)
*
|
2021-05-10 |
2022-11-17 |
Q-State Biosciences, Inc. |
Compositions targeting sodium channel 1.6
|
US20240240183A1
(en)
|
2021-05-25 |
2024-07-18 |
National University Corporation Tokyo Medical And Dental University |
Heteronucleic acid containing scpBNA or AmNA
|
BR112023024384A2
(pt)
|
2021-05-31 |
2024-02-15 |
Rena Therapeutics Inc |
Complexo de ácido nucleico ligado ao ligante
|
AU2022293556A1
(en)
|
2021-06-18 |
2024-01-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ifnar1 expression
|
MX2023015509A
(es)
|
2021-06-23 |
2024-01-22 |
Entrada Therapeutics Inc |
Compuestos antisentido y metodos para dirigirse a repeticiones cug.
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
EP4389891A1
(de)
|
2021-08-19 |
2024-06-26 |
National University Corporation Tokyo Medical and Dental University |
Modifizierte heteronukleinsäure mit morpholinonukleinsäure
|
WO2023026994A1
(ja)
|
2021-08-21 |
2023-03-02 |
武田薬品工業株式会社 |
ヒトトランスフェリンレセプター結合ペプチド-薬物コンジュゲート
|
EP4396352A2
(de)
|
2021-09-01 |
2024-07-10 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur reduzierung der dmpk-expression
|
JPWO2023042876A1
(de)
|
2021-09-15 |
2023-03-23 |
|
|
WO2023054350A1
(ja)
|
2021-09-28 |
2023-04-06 |
住友化学株式会社 |
精製ジクロロ酢酸の製造方法
|
WO2023080159A1
(ja)
|
2021-11-02 |
2023-05-11 |
レナセラピューティクス株式会社 |
リガンド結合核酸複合体
|
CN118318042A
(zh)
|
2021-11-03 |
2024-07-09 |
豪夫迈·罗氏有限公司 |
用于调节载脂蛋白e4表达的寡核苷酸
|
CN118284695A
(zh)
|
2021-11-11 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
用于治疗hbv的药物组合
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
WO2023178144A2
(en)
|
2022-03-16 |
2023-09-21 |
Empirico Inc. |
Galnac compositions for improving sirna bioavailability
|
US11931421B2
(en)
|
2022-04-15 |
2024-03-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
EP4332221A1
(de)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose-nukleinsäure-antisense-oligonukleotide und verfahren dafür
|
WO2024073386A1
(en)
*
|
2022-09-29 |
2024-04-04 |
Celanese Eva Performance Polymers Llc |
Implantable medical device for the delivery of a nucleic acid
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|